艾司奥美拉唑镁肠溶片三联方案治疗幽门螺杆菌阳性十二指肠溃疡的效果
|
摘要
目的观察艾司奥美拉唑镁肠溶片三联方案治疗幽门螺杆菌(Hp)阳性十二指肠溃疡的临床疗效。方法利用数字表法将本院80例Hp阳性十二指肠溃疡病例随机分为2组,各40例。对照组采取奥美拉唑三联方案,实验组采取艾司奥美拉唑镁肠溶片三联方案,比较2组治疗前后溃疡面积、腹痛评分、Hp根除率与溃疡愈合率。观察2组腹痛缓解、不良反应情况及临床疗效。结果治疗后,2组溃疡面积比较差异无统计学意义(P> 0. 05);实验组腹痛评分显著低于对照组(P <0. 05);实验组第1、2天腹痛缓解率显著高于对照组(P <0. 05),但2组第3、7天腹痛缓解率、Hp根除率、溃疡愈合率、总有效率、不良反应总发生率比较无显著差异(P> 0. 05)。结论与奥美拉唑三联方案相比,艾司奥美拉唑镁肠溶片三联方案可有效缓解Hp阳性十二指肠溃疡患者腹痛症状,临床疗效显著,且不良反应少。
Objective To observe the clinical effect of Esomeprazole Magnesium EntericCoated Tablets triple regimen in the treatment of Helicobacter pylori( Hp) positive duodenal ulcer.Methods A total of 80 patients with Hp positive duodenal ulcer in the hospital were randomly divided into two groups by random number table method,with 40 cases in each group. The control group was treated with Esomeprazole triple therapy,while the experimental group was treated with Esomeprazole Magnesium Enteric-Coated Tablets triple therapy. The ulcer area,abdominal pain score,Hp eradication rate and ulcer healing rate were compared between the two groups before and after treatment. The relief of abdominal pain,adverse reactions and clinical curative effect in the two groups were observed.Results After treatment,there was no significant difference in the ulcer area between the two groups( P > 0. 05),and the abdominal pain score of the experimental group was significantly lower than that of the control group( P < 0. 05). The remission rates of abdominal pain in the experimental group on the 1 stand 2 ndday were significantly higher than that in the control group( P < 0. 05). There were no significant differences between the two groups in the remission rates of abdominal pain on the 3 rdor 7 th day,Hp eradication rate,ulcer healing rate,the total effective rate or the total incidence of adverse reactions( P > 0. 05). Conclusion Compared with Esomeprazole triple regimen,Esomeprazole Magnesium Enteric-Coated Tablets triple therapy can effectively relieve abdominal pain in patients with Hp positive duodenal ulcer,with significant clinical efficacy and less side effects.
Objective To observe the clinical effect of Esomeprazole Magnesium EntericCoated Tablets triple regimen in the treatment of Helicobacter pylori( Hp) positive duodenal ulcer.Methods A total of 80 patients with Hp positive duodenal ulcer in the hospital were randomly divided into two groups by random number table method,with 40 cases in each group. The control group was treated with Esomeprazole triple therapy,while the experimental group was treated with Esomeprazole Magnesium Enteric-Coated Tablets triple therapy. The ulcer area,abdominal pain score,Hp eradication rate and ulcer healing rate were compared between the two groups before and after treatment. The relief of abdominal pain,adverse reactions and clinical curative effect in the two groups were observed.Results After treatment,there was no significant difference in the ulcer area between the two groups( P > 0. 05),and the abdominal pain score of the experimental group was significantly lower than that of the control group( P < 0. 05). The remission rates of abdominal pain in the experimental group on the 1 stand 2 ndday were significantly higher than that in the control group( P < 0. 05). There were no significant differences between the two groups in the remission rates of abdominal pain on the 3 rdor 7 th day,Hp eradication rate,ulcer healing rate,the total effective rate or the total incidence of adverse reactions( P > 0. 05). Conclusion Compared with Esomeprazole triple regimen,Esomeprazole Magnesium Enteric-Coated Tablets triple therapy can effectively relieve abdominal pain in patients with Hp positive duodenal ulcer,with significant clinical efficacy and less side effects.
引文
[1]张克明.基层医院腹腔镜下胃十二指肠穿孔修补术的临床疗效研究[J].湖南师范大学学报:医学版,2015,12(2):65-67.
[2]叶邦梅,张燕玲.半夏泻心汤治疗幽门螺杆菌感染十二指肠溃疡的临床疗效观察[J].中国基层医药,2017,24(13):2010-2014.
[3]祝盈,吴月凤,朱洁,等. POSSUM评分在胰十二指肠切除术后并发症精准化护理干预中的应用[J].蚌埠医学院学报,2016,41(7):959-962.
[4]张雪莲,王一平,吴维宇,等.四联疗法联合口腔洁治根除消化性溃疡合并幽门螺杆菌感染的疗效研究[J].成都医学院学报,2017,12(5):576-578.
[5]池卫明,朱燕莉,张海.埃索美拉唑三联疗法对十二指肠溃疡患者血清TNF-α及HMGB1表达的影响[J].实用药物与临床,2016,19(7):886-889.
[6]潘慧人,黄深荣,邹铭斐.雷贝拉唑三联疗法联合溃疡汤治疗脾虚湿盛型十二指肠溃疡疗效观察[J].现代中西医结合杂志,2015,24(1):53-54.
[7]卢万可,宋辉,陶伍元.埃索美拉唑联合抗菌药物治疗十二指肠溃疡临床观察[J].西北药学杂志,2016,31(4):419-421.
[8]苏荣.影响十二指肠球部溃疡患者复发的危险因素分析[J].山西医药杂志,2016,45(11):1316-1319.
[9]张慧,李晓宇,崔梅花,等.口腔幽门螺杆菌感染对胃内幽门螺杆菌根除疗效的影响及其相关因素研究[J].中国全科医学,2016,19(11):1242-1246.
[10]胡雪,马静静,田山,等.大蒜素治疗幽门螺杆菌阳性十二指肠溃疡的Meta分析[J].海南医学,2017,28(17):2898-2902.
[11]邵海燕,刘洁,王佳瑞,等.奥美拉唑+克拉霉素+阿莫西林治疗Hp阳性十二指肠溃疡患者疗效及其对血清HMGB1、NF-κB和TNF-α的影响[J].疑难病杂志,2017,16(6):584-587.
[12]林常青,李莉群,邹燕敦,等.十二指肠溃疡患者应用泮托拉唑钠与奥美拉唑治疗的有效性和安全性分析[J].现代消化及介入诊疗,2016,21(4):644-646.
[13]王经荣,郑梅英.胃铋镁联合三联疗法治疗幽门螺杆菌阳性十二指肠球部溃疡的效果[J].中国医药导报,2015,12(29):112-115.
[14]曾毅,叶雨彤,梁德森,等.兰索拉唑与奥美拉唑治疗幽门螺杆菌阳性十二指肠溃疡的Meta分析[J].广西医学,2015,37(7):1013-1015.
[15] R9hss K,Hasselgren G,Hedenstr9m H. Effect of EsEsomeprazole 40 mg vs Esomeprazole 40 mg on 24-Hour Intragastric pH in Patients with Symptoms of Gastroesophageal Reflux Disease[J]. Digestive Diseases&Sciences,2002,47(5):954-958.
[16]胡向青,郝福,巴晓雨,等.艾司奥美拉唑镁肠溶片溶出曲线相似性评价[J].国际药学研究杂志,2016,43(6):1135-1139.
[17]巴晓雨,闫朝雷,郝福,等.艾司奥美拉唑镁肠溶片微生物限度检查法的建立[J].海峡药学,2017,29(6):30-32.
[18]王炳英.埃索美拉唑、奥美拉唑为主的三联疗法治疗幽门螺杆菌阳性消化性溃疡效果比较[J].山东医药,2015,7(38):77-78.
[19]陈丽,黄锦文,邱嘉华.埃索美拉唑三联疗法对幽门螺杆菌阳性十二指肠溃疡的作用[J].西北药学杂志,2015,30(5):621-623.
[20]杨忠兰,吴云峰,田茂超,等.雷贝拉唑联合抗生素序贯疗法治疗幽门螺杆菌阳性消化性溃疡疗效及预后分析[J].中国现代医学杂志,2015,25(18):91-94.
[2]叶邦梅,张燕玲.半夏泻心汤治疗幽门螺杆菌感染十二指肠溃疡的临床疗效观察[J].中国基层医药,2017,24(13):2010-2014.
[3]祝盈,吴月凤,朱洁,等. POSSUM评分在胰十二指肠切除术后并发症精准化护理干预中的应用[J].蚌埠医学院学报,2016,41(7):959-962.
[4]张雪莲,王一平,吴维宇,等.四联疗法联合口腔洁治根除消化性溃疡合并幽门螺杆菌感染的疗效研究[J].成都医学院学报,2017,12(5):576-578.
[5]池卫明,朱燕莉,张海.埃索美拉唑三联疗法对十二指肠溃疡患者血清TNF-α及HMGB1表达的影响[J].实用药物与临床,2016,19(7):886-889.
[6]潘慧人,黄深荣,邹铭斐.雷贝拉唑三联疗法联合溃疡汤治疗脾虚湿盛型十二指肠溃疡疗效观察[J].现代中西医结合杂志,2015,24(1):53-54.
[7]卢万可,宋辉,陶伍元.埃索美拉唑联合抗菌药物治疗十二指肠溃疡临床观察[J].西北药学杂志,2016,31(4):419-421.
[8]苏荣.影响十二指肠球部溃疡患者复发的危险因素分析[J].山西医药杂志,2016,45(11):1316-1319.
[9]张慧,李晓宇,崔梅花,等.口腔幽门螺杆菌感染对胃内幽门螺杆菌根除疗效的影响及其相关因素研究[J].中国全科医学,2016,19(11):1242-1246.
[10]胡雪,马静静,田山,等.大蒜素治疗幽门螺杆菌阳性十二指肠溃疡的Meta分析[J].海南医学,2017,28(17):2898-2902.
[11]邵海燕,刘洁,王佳瑞,等.奥美拉唑+克拉霉素+阿莫西林治疗Hp阳性十二指肠溃疡患者疗效及其对血清HMGB1、NF-κB和TNF-α的影响[J].疑难病杂志,2017,16(6):584-587.
[12]林常青,李莉群,邹燕敦,等.十二指肠溃疡患者应用泮托拉唑钠与奥美拉唑治疗的有效性和安全性分析[J].现代消化及介入诊疗,2016,21(4):644-646.
[13]王经荣,郑梅英.胃铋镁联合三联疗法治疗幽门螺杆菌阳性十二指肠球部溃疡的效果[J].中国医药导报,2015,12(29):112-115.
[14]曾毅,叶雨彤,梁德森,等.兰索拉唑与奥美拉唑治疗幽门螺杆菌阳性十二指肠溃疡的Meta分析[J].广西医学,2015,37(7):1013-1015.
[15] R9hss K,Hasselgren G,Hedenstr9m H. Effect of EsEsomeprazole 40 mg vs Esomeprazole 40 mg on 24-Hour Intragastric pH in Patients with Symptoms of Gastroesophageal Reflux Disease[J]. Digestive Diseases&Sciences,2002,47(5):954-958.
[16]胡向青,郝福,巴晓雨,等.艾司奥美拉唑镁肠溶片溶出曲线相似性评价[J].国际药学研究杂志,2016,43(6):1135-1139.
[17]巴晓雨,闫朝雷,郝福,等.艾司奥美拉唑镁肠溶片微生物限度检查法的建立[J].海峡药学,2017,29(6):30-32.
[18]王炳英.埃索美拉唑、奥美拉唑为主的三联疗法治疗幽门螺杆菌阳性消化性溃疡效果比较[J].山东医药,2015,7(38):77-78.
[19]陈丽,黄锦文,邱嘉华.埃索美拉唑三联疗法对幽门螺杆菌阳性十二指肠溃疡的作用[J].西北药学杂志,2015,30(5):621-623.
[20]杨忠兰,吴云峰,田茂超,等.雷贝拉唑联合抗生素序贯疗法治疗幽门螺杆菌阳性消化性溃疡疗效及预后分析[J].中国现代医学杂志,2015,25(18):91-94.